Home   >   News   >   Health   >   201203
Norvatis Pharma introduces new diabetes and hypertension drugs   
 
  << Prev  |  Next >>
 
02-Mar-2012  
Comments ( 0 )     Email    Print
       
 
 
 
 
Related Stories
 
Novartis Pharma, a pharmaceutical company based in Switzerland, on Thursday introduced news diabetes and hypertension drugs called Galvus and Exforge HCT respectively, on the Ghanaian market.

The drugs which are imported by the Ghana branch of the company is to help deal with the two conditions as a growing number of people in Ghana and on the African continent as getting the diabetes and hypertension.

Addressing the press after introducing the drugs to some medical officers, Mr Roland Addo-Hammond, Ghana Branch Manager, said the drug does not make users gain weight as is peculiar with the normal diabetes drug on the market and cost only 1.50p per tablet.

He said the Galvus which is already on the market, can effectively fight Type 2 diabetes which usually affects persons above 30 years can be used alone as compared to other diabetic drug which required combination of drugs.

He said the company would partner with the Diabetic Association of Ghana in an effort to make the drug known to them.

“We will also soon embark on free medical screening exercises for the general public as part of our social responsibility.”

In a presentation, Dr Ben Eghan, Head of the Diabetes Unit, Komfo Anokye Hospital, noted that a report released in 201, indicated that 366 million people in the world were suffering from diabetes.

“By 2030, the statistics would have increased to 552 million people with about 80% of them living in low income countries.”

He urged diabetic patients to desist from alcohol intake, smoking and engage frequently in physical activities to keep fit.
 
 
 
 

Comments ( 0 ): Post Your Comments >>

 
 
 
Disclaimer: Opinions expressed here are those of the writers and do not reflect those of Peacefmonline.com. Peacefmonline.com accepts no responsibility legal or otherwise for their accuracy of content. Please report any inappropriate content to us, and we will evaluate it as a matter of priority.
 
 
Featured Video